Read More

Takeda Earlier Announced Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT. No New Safety Signals Were Seen

TAK

Read More

Mainz Biomed Executed Its Option From Uni Targeting Research To Acquire The Previously Licensed Scientific Intellectual Property For Its Flagship Product Coloalert, A Detection Test For Colorectal Cancer

The Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. to outright purchase intellectual property, including a pending patent, associated with a portfolio of novel gene

MYNZ